v3.26.1
STOCK OPTIONS AND RESTRICTED STOCK UNITS
 3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
STOCK OPTIONS AND RESTRICTED STOCK UNITS

NOTE 11 – STOCK OPTIONS AND RESTRICTED STOCK UNITS

 

The following table presents the Company’s stock option activity for employees and directors of the Company for the three months ended March 31, 2026:

 

   Number of Options   Weighted Average Exercise Price 
Outstanding at December 31, 2025   119    3,741.73 
Granted   -    - 
Exercised   -    - 
Forfeited or expired   (27)   52.75 
Outstanding at March 31, 2026   92    3,741.73 
Number of options exercisable at March 31, 2026   92    3,741.73 

 

The aggregate intrinsic value of the awards outstanding as of March 31, 2026 was $0. These amounts represent the total intrinsic value, based on the Company’s stock price of $4.62 as of March 31, 2026, less the weighted exercise price. This represents the potential amount received by the option holders had all option holders exercised their options as of that date.

 

On October 20, 2025, the Company granted 20,928 restricted stock units (“RSUs”) to Mr. Alon Silberman under the Company’s 2022 Share Incentive Plan. The RSUs vest in three equal annual installments on each of the first, second and third anniversaries of the grant date, subject to continued employment with MitoCareX.

 

Costs incurred in respect of stock-options and RSUs compensation for employees and directors for the three months ended March 31, 2026 and 2025 were $90 and less than $1, respectively.